Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2006 2
2007 1
2008 4
2009 10
2010 16
2011 46
2012 92
2013 111
2014 157
2015 183
2016 318
2017 350
2018 347
2019 397
2020 517
2021 596
2022 688
2023 628
2024 313

Text availability

Article attribute

Article type

Publication date

Search Results

4,235 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean linagliptin or dapagliflozin (4,185 results)?
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
Participants in the placebo group were randomly reassigned (1:1:1) in a double-blinded manner at week 26 to linagliptin 5 mg or one of the empagliflozin doses (10 mg or 25 mg). ...Adverse events occurred in 34 (64%) participants in the placebo group, 40 (77%) in the …
Participants in the placebo group were randomly reassigned (1:1:1) in a double-blinded manner at week 26 to linagliptin 5 mg or one o …
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. DeFronzo RA, et al. Diabetes Care. 2015 Mar;38(3):384-93. doi: 10.2337/dc14-2364. Epub 2015 Jan 12. Diabetes Care. 2015. PMID: 25583754 Clinical Trial.
RESEARCH DESIGN AND METHODS: Subjects were randomized to a combination of empagliflozin 25 mg/linagliptin 5 mg (n = 137), empagliflozin 10 mg/linagliptin 5 mg (n = 136), empagliflozin 25 mg (n = 141), empagliflozin 10 mg (n = 140), or …
RESEARCH DESIGN AND METHODS: Subjects were randomized to a combination of empagliflozin 25 mg/linagliptin 5 mg (n = 137), e …
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes.
Korbut AI, Taskaeva IS, Bgatova NP, Muraleva NA, Orlov NB, Dashkin MV, Khotskina AS, Zavyalov EL, Konenkov VI, Klein T, Klimontov VV. Korbut AI, et al. Int J Mol Sci. 2020 Apr 23;21(8):2987. doi: 10.3390/ijms21082987. Int J Mol Sci. 2020. PMID: 32340263 Free PMC article.
Eight-week-old male db/db mice were randomly assigned to treatment with empagliflozin, linagliptin, empagliflozin-linagliptin or vehicle for 8 weeks. ...Renal LC3B and Bcl-2 were restored in actively treated animals. LAMP-1 expression was enhanced in t …
Eight-week-old male db/db mice were randomly assigned to treatment with empagliflozin, linagliptin, empagliflozin-li …
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES, Deeks ED. Kim ES, et al. Drugs. 2015 Sep;75(13):1547-57. doi: 10.1007/s40265-015-0457-z. Drugs. 2015. PMID: 26323340 Review.
Results of two randomized controlled trials of 52 weeks' duration in adults with T2D demonstrated that empagliflozin/linagliptin improved glycaemic control significantly more than linagliptin when administered as initial therapy (whereas results vs. empagl …
Results of two randomized controlled trials of 52 weeks' duration in adults with T2D demonstrated that empagliflozin/linagliptin …
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Rosenstock J, et al. JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269. JAMA. 2019. PMID: 30418475 Free PMC article. Clinical Trial.
Final follow-up occurred on January 18, 2018. INTERVENTIONS: Patients were randomized to receive linagliptin, 5 mg once daily (n = 3494), or placebo once daily (n = 3485) added to usual care. ...MAIN OUTCOMES AND MEASURES: Primary outcome was time to first occurrence of th …
Final follow-up occurred on January 18, 2018. INTERVENTIONS: Patients were randomized to receive linagliptin, 5 mg once daily (n = 34 …
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
Woo V. Woo V. Int J Clin Pract. 2015 Dec;69(12):1427-37. doi: 10.1111/ijcp.12720. Epub 2015 Aug 25. Int J Clin Pract. 2015. PMID: 26303997 Free PMC article. Review.
AIM: The aim of this study was to describe the latest clinical evidence on the efficacy and safety profiles of empagliflozin/linagliptin STCs in comparison with the individual components. ...CONCLUSION: Empagliflozin/linagliptin STC appears to be a rat …
AIM: The aim of this study was to describe the latest clinical evidence on the efficacy and safety profiles of empagliflozin/linag …
Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X, Hu J. Tan X, et al. Ann Endocrinol (Paris). 2016 Oct;77(5):557-562. doi: 10.1016/j.ando.2015.11.003. Epub 2016 Apr 6. Ann Endocrinol (Paris). 2016. PMID: 27062036 Review.
Glyxambi() (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2) inhibitor with a dipeptidyl peptidase-4 (DPP-4) inhibitor. Glyxambi() is served as an adjuvant to diet and exercise to improve glycemic cont …
Glyxambi() (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2) …
Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data.
Gabriel R, Boukichou Abdelkader N, Acosta T, Gilis-Januszewska A, Gómez-Huelgas R, Makrilakis K, Kamenov Z, Paulweber B, Satman I, Djordjevic P, Alkandari A, Mitrakou A, Lalic N, Colagiuri S, Lindström J, Egido J, Natali A, Pastor JC, Teuschl Y, Lind M, Silva L, López-Ridaura R, Tuomilehto J; e-PREDICE Consortium. Gabriel R, et al. PLoS One. 2020 Apr 13;15(4):e0231196. doi: 10.1371/journal.pone.0231196. eCollection 2020. PLoS One. 2020. PMID: 32282852 Free PMC article. Clinical Trial.
INTERVENTION: Participants were randomized to placebo; metformin 1.700 mg/day; linagliptin 5 mg/day or fixed-dose combination of linagliptin/metformin. ...RESULTS: One thousand three hundred ninety one individuals with hyperglycaemia were assessed for eligibility, 4 …
INTERVENTION: Participants were randomized to placebo; metformin 1.700 mg/day; linagliptin 5 mg/day or fixed-dose combination of l …
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Gallwitz B. Gallwitz B. Expert Opin Drug Saf. 2017 Dec;16(12):1399-1405. doi: 10.1080/14740338.2017.1382471. Epub 2017 Oct 11. Expert Opin Drug Saf. 2017. PMID: 28934557 Review.
Areas covered: An overview on the clinical studies investigating the combination therapy with the DPP-4i linagliptin and the SGLT-2i empagliflozin is given. The clinical evidence for the efficacy and safety of free combinations as well as for their fixed dose combin …
Areas covered: An overview on the clinical studies investigating the combination therapy with the DPP-4i linagliptin and the SGLT-2i …
Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Jain RK. Jain RK. Expert Opin Pharmacother. 2017 Apr;18(6):545-549. doi: 10.1080/14656566.2017.1299712. Epub 2017 Apr 4. Expert Opin Pharmacother. 2017. PMID: 28375658
Although various single-pill combinations of oral glucose-lowering agents are available, empagliflozin/linagliptin was the first approved combination of a sodium glucose co-transporter 2 (SGLT2) inhibitor with a dipeptidyl peptidase 4 (DPP-4) inhibitor in the United …
Although various single-pill combinations of oral glucose-lowering agents are available, empagliflozin/linagliptin was the fir …
4,235 results